NASDAQ · DNTH
Dianthus Therapeutics, Inc.
$82.70+$0.39 (+0.47%)
Dianthus Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.84% below the high.
Loading market information…
NASDAQ · ORKA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Oruka Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 16.33% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Oruka Therapeutics, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.60. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Oruka Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:45 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 6, 2025 |
| -$0.49+27.94% vs estimate |
| $0.00 |
| Q3 2024 | Nov 13, 2024 | -$1.46-265.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $120.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$82.70+$0.39 (+0.47%)
Dianthus Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.84% below the high.
$29.21-$0.78 (-2.6%)
Xencor, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.07% below the high.
$48.64-$1.86 (-3.68%)
AnaptysBio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.78% below the high.
$12.57+$0.26 (+2.11%)
MoonLake Immunotherapeutics’s quoted price sits in the lower half of its reported 52-week range, 46.03% below the high.
$19.83+$0.29 (+1.48%)
Odyssey Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.74% below the high.
$6.89-$0.24 (-3.37%)
Alumis Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.02% below the high.
$15.27-$0.53 (-3.35%)
Attovia Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.46% below the high.
$3.99+$0.03 (+0.76%)
Aclaris Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.55% below the high.
